Iomai Corporation
Iomai Corporation discovers and develops vaccines and immune system stimulants, delivered via a novel, needle-free technology called
About Iomai Corporation
Iomai Corporation, established in 1997, operated as a biotechnology firm focused on the development of vaccines and immune system stimulants. The company was founded by Dr. Gregory Glenn, a medical doctor from the Walter Reed Army Institute of Research (WRAIR), and Dean Lewis, who was an employee at the World Bank. Dr. Glenn's background in pediatrics and as a clinical and basic research scientist at WRAIR, where he focused on translational vaccine research, was fundamental to Iomai's scientific direction. He pioneered concepts in needle-free vaccine delivery and adjuvants, bringing several products from concept to clinical development.
The core of Iomai's business was its proprietary transcutaneous immunization (TCI) technology. This needle-free approach leveraged the unique properties of the skin's immune cells, specifically Langerhans cells, to deliver vaccines and elicit a strong immune response. The technology was initially discovered by researchers at WRAIR. Iomai's business model revolved around leveraging this TCI platform to enhance existing vaccines, create new vaccines that were only viable through skin administration, and expand the overall vaccine market. The company's product development pipeline included four candidates, with a leading program for a traveler's diarrhea vaccine patch, which entered Phase 3 trials in 2009. Other programs targeted influenza and pandemic flu.
Iomai's primary product was a vaccine patch that offered a painless and simple alternative to injections. A key feature was its ability to deliver an adjuvant, a substance that boosts the immune response, directly to the skin. This could make vaccines more effective, potentially allowing for smaller doses—a critical advantage in a pandemic situation. For instance, the company was developing an immunostimulant patch designed to be applied over an injection site to increase the immune response to an injected vaccine. In 2007, Iomai secured a significant $128 million contract with the U.S. government to develop a dose-sparing patch for a pandemic influenza vaccine. The company also engaged in collaborations, such as a 2008 agreement with Merck & Co. to conduct preclinical studies with its immunostimulant patch.
A significant milestone in the company's history was its acquisition by the Austrian vaccine company Intercell AG in 2008. The deal was valued at approximately $189 million. The acquisition gave Intercell full rights to Iomai's late-stage traveler's diarrhea vaccine and its needle-free patch technology. At the time of the acquisition, Iomai employed around 110 people. Stanley C. Erck, who had served as President and CEO of Iomai since 2000, led the company through its initial public offering and the merger with Intercell.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | May 2008 | $0 | — | Intercell | — |
| SERIES COther financing | Jan 2003 | $54M | $216M | NEA · Essex Woodlands Health Ventures · MedImmune Ventures · EW Healthcare Partners | — |
Growth signals
Latest recorded traffic for Iomai Corporation is 140 monthly website visits, down 80.3% over the last three months. Iomai Corporation's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Iomai Corporation in the Gaithersburg ecosystem
The Iomai Corporation office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
NEA
EW Healthcare Partners
Essex Woodlands Health Ventures
MedImmune Ventures
Other known investors2 additional known investors
Intercell
Stanford University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Iomai Corporation on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Iomai Corporation’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








